毛斐-2024欧洲杯平台官网

毛斐，博士，副教授

地址：梅陇路130号实验18楼431室

email：

个人简介

2014年6月毕业于中山大学药学院药物化学专业，获博士学位，后进入华东理工大学药学院从事博士后研究，合作导师为李剑教授。2016年10月出站后留校工作，从事药物化学教学和科研工作，2018年9月晋升副教授。

作为项目负责人，先后主持国家自然科学基金青年基金1项、面上项目1项、上海市自然科学基金面上项目1项、博士后科学基金（面上一等资助）1项、教育部高校基本科研业务费1项；2017年入选上海市“青年科技英才扬帆计划”；2018年入选华东理工大学“青年英才培育计划”a类；作为研究骨干参与国家新药创制重大专项1项，国家重点研发计划课题1项。

迄今已在国内外重要刊物如j. med. chem.; eur. j. med. chem.; acs chem. neurosci.等上发表sci论文50余篇；申请发明专利20项（授权11项）；参编论著1部（药物结构优化——设计策略和经验规则）。

教育经历

2009.9 – 2014.6，中山大学，药学院，药物化学，博士；

2005.8 – 2009.6，沈阳药科大学，制药工程学院，应用化学，学士。

工作经历

2018.9 – 至今，华东理工大学，药学院，副教授；

2016.11 – 2018.8，华东理工大学，药学院，讲师；

2014.7 – 2016.10，华东理工大学，药学院，师资博士后。

主要研究方向

1. 抗肿瘤创新药物开发研究

2. 多靶点抗ad创新药物发现研究

3. 抗耐药菌创新药物开发研究

4. 老药二次开发研究  

代表性论文 (^#共同第一作者，*为通讯作者)

1.   linghao hu^#, hongxuan feng^#,hongguang zhang, songda yu, qinyuan zhao, wei wang, fengxia bao, xun ding, jiajing hu, manjiong wang, yixiang xu, zengrui wu, xiaokang li, yun tang, fei mao*, xiaoyan chen, haiyan zhang*, jian li*. development of novel n-hydroxypyridone derivatives as potential anti-ischemic stroke agents. j. med. chem. 2020, 63, 1051-1067.

2.  yang chen^#, yunxia cui^#, xiao sun^#, huiwen wu, manjiao ou, yunzhe tang, shuaishuai ni, xiaokang li, jin zhu, fei mao*, yudong wang* and jian li*. repurposing of antipsychotics perphenazine for the treatment of endometrial cancer. bioorg. med. chem lett. 2020, 30, 127239.

3. wenwen liu^#, huan wang^#, xiaokang li^#, yixiang xu, jian zhang, wei wang, qi gong, xiaoxia qiu, jin zhu, fei mao*, haiyan zhang*, jian li*. design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. bioorg. med. chem. 2018, 26, 3117–3125.

4. wei ni^#, huan wang^#, xiaokang li^#, xinyu zheng^#, manjiong wang, jian zhang, qi gong, dazheng ling, fei mao*, haiyan zhang*, jian li*. novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (ache) and phosphodiesterase 5 (pde5). acs chem. neurosci. 2018, 9, 1625–1636.

5. baoli li^#, shuaishuai ni^#, fei mao^#, feifei chen, yifu liu, hanwen wei, wenhua chen, jin zhu, lefu lan*, jian li*. novel terminal bipheny-based diapophytoene desaturases (crtn) inhibitors as anti-mrsa/visr/lrsa agents with reduced herg activity. j. med. chem. 2018, 61, 224–250.

6. fei mao^#, huan wang^#, wei ni^#, xinyu zheng, manjiong wang, keting bao, dazheng ling, xiaokang li, yixiang xu, haiyan zhang*, jian li*. design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (ache) and phosphodiesterase 5 (pde5) for the treatment of alzheimer’s disease. acs chem. neurosci. 2018, 9, 328–345.

7. hanwen wei^#, fei mao^#, shuaishuai ni^#, feifei chen, baoli li, xiaoxia qiu, linghao hu, manjiong wang, xinyu zheng, jin zhu, lefu lan*, jian li*. discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant staphylococcus aureus infections. eur. j. med. chem. 2018, 145, 235–251.

8. yi-xiang xu^#, huan wang^#, xiao-kang li, sheng-nan dong, wen-wen liu, qi gong, tian-duan-yi wang, yun tang, jin zhu, jian li*, hai-yan zhang*, fei mao*. discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of alzheimer's disease. eur. j. med. chem. 2018, 143, 33–47.

9. xiaokang li^#, huan wang^#, yixiang xu, wenwen liu, xiaoxia qiu, jin zhu, fei mao*, haiyan zhang*, jian li*. novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation. acs chem. neurosci. 2017, 8, 2708–2721.

10. yanli lu^#, fei mao^#, xiaokang li, xinyu zheng, manjiong wang, qing xu, jin zhu, and jian li*. discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-kit/pdgfrα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (gists). j. med. chem. 2017, 60, 5099–5119.

11. xiaokang li^#, huan wang^#, zhengyu lu, xinyu zheng, wei ni, jin zhu, yan fu, fulin lian, naixia zhang, jian li*, haiyan zhang*, and fei mao*. development of multifunctional pyrimidinylthiourea derivatives as potential anti-alzheimer agents. j. med. chem. 2016, 59, 8326−8344.

12. fei mao^#, qingya kong^#, wei ni, xiang xu, dazheng ling, zhengyu lu, jian li*. melting point distribution analysis of the global approved and discontinued drugs: a research for improving the success chance of drug design and discovery. chemistryopen, 2016, 5, 357–368.

13. fei mao, wei ni, xiang xu, hui wang, jing wang, min ji, jian li*. chemical structure-related drug-like criteria of global approved drugs. molecules 2016, 21, 75; doi:10.3390/molecules21010075.

14. dengwei wu^#, fei mao^#, yan ye, jian li, chuanlian xu*, xiaomin luo, jing chen*, xu shen. policresulen as a novel inhibitor of ns2b/ns3 protease efficiently suppressed the replication of denv2 virus. acta pharmacol. sin. 2015, 36, 1126-1136.

15. fei mao, jianheng li, hui wei, ling huang*, xingshu li*. 2015,30, 995-1001.

16. fei mao, jun yan, jian-heng li, yang sun, xian jia, ling huang*, xing-shu li*. new multi-target-directed small molecules against alzheimer's disease: a combination of resveratrol and clioquinol. org. biomol. chem. 2014, 12, 5936-5944.

17. fei mao, jian-wen chen*, qi zhou, zong-hua luo, li huang, xing-shu li*. novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. bioorg. med. chem. lett.2013, 23, 6737-6742.

18. fei mao, ling huang, zong-hua luo, anqiu liu, chuan-jun lu, zhi-yong xie*, xingshu li*. o-hydroxyl or o-amino benzylamine-tacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation. bioorgan. med. chem.2012, 20, 5884-5892.